Opioid Pharmacotherapy
View AllContinuing Education
Persistent and Breakthrough Cancer Pain: An Expert Video Roundtable
Neal E. Slatkin
2012 Feb 02.
Barbara A. Murphy
2012 Jan 24.
Sharon M. Weinstein
2012 Jan 24.
David M. Kaufman
2011 Oct 03.
Prescribing Opioids for Pain: Challenges and Solutions
Marc N. Gourevitch
2011 Jun 28.
Joanna L. Starrels
2011 Jun 28.
- Acute and Post-Operative Pain
- Cancer-related Pain
- Chronic Noncancer Pain
- Comorbid Conditions
- Fibromyalgia
- Headache
- Interventional Modalites
- Low Back Pain
- Medico-Legal-Ethical Issues
- Neuropathic Pain
- Nonopioid Pharmacotherapy
- Nonpharmacologic Treatment
- Opioid Pharmacotherapy
- Osteoarthritis
- Palliative Care
- Risk Management
- Scientific Perspectives
- Special Patient Populations
Journals
Select your area of interest:
PubMed Search
Enter search terms here.
Section Editor
Scott M. Fishman, MD
User Activity
Scott M. Fishman, MD
Chief, Division of Pain Medicine
Professor of Anesthesiology
Department of Anesthesiology and Pain Medicine
University of California, Davis
Davis, California
Lynn R. Webster, MD
User Activity
Lynn R. Webster, MD
Continuing Education Activities
Medical Director
Lifetree Clinical Research and Pain Clinic
Salt Lake City, Utah
View AllPublications
Chronic opioid therapy and preventive services in rural primary care: an Oregon rural practice-based research network study.
Association between urine drug test results and treatment outcome in high-risk chronic pain patients on opioids
Drug testing, chronic pain,and financial conflicts of interest
Painful Diabetic Peripheral Neuropathy: Consensus Recommendations on Diagnosis, Assessment and Management.
The metabolism of opioid agents and the clinical impact of their active metabolites.
Buckley DI, Calvert JF, Lapidus JA, et al.
Ann Fam Med. 2010;8(3):237-44.
PURPOSE:...
Ann Fam Med. 2010;8(3):237-44.
PURPOSE:...
Association between urine drug test results and treatment outcome in high-risk chronic pain patients on opioids
Barth KS, Becker WC, Wiedemer NL, Mavandadi S, Oslin DW, Meghani SH, Gallagher RM.
J Addict...
J Addict...
Drug testing, chronic pain,and financial conflicts of interest
Collen M, Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR.
Am J Manag Care. 2011 Apr...
Am J Manag Care. 2011 Apr...
Painful Diabetic Peripheral Neuropathy: Consensus Recommendations on Diagnosis, Assessment and Management.
Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, Vinik A, Boulton A; on...
The metabolism of opioid agents and the clinical impact of their active metabolites.
Smith HS.
Clin J Pain. 2011 Nov;27(9):824-38.
BACKGROUND: The metabolism of opioids is...
Clin J Pain. 2011 Nov;27(9):824-38.
BACKGROUND: The metabolism of opioids is...
Clinician.com Links
The regulatory and reimbursement environment surrounding drug testing is becoming increasingly stringent.
As the population ages, more individuals will be living with chronic pain, resulting in increased morbidity, mortality, and healthcare utilization.
Buprenorphine is a partial μ-opioid receptor agonist that is used the treatment of chronic pain and opioid addiction.
The World Health Organization has stated that undertreated pain is the number one health problem in America. Sharp rises in unintentional prescription drug overdose rates, however, have caused regulators to move to restrict access to prescription opioids and other potentially abusable medications classes.
Opioid analgesics are increasingly being prescribed for the management of chronic pain despite incomplete evidence for long-term efficacy and the ongoing risk of abuse.
Therapeutic prescription of opioid analgesics has risen sharply in the United States over the last two decades.
Chronic noncancer pain is a leading cause of disability, resulting in deleterious effects on multiple patient domains (eg, physical, psychological, cognitive, employment, among others).
During the last two decades, reports of inadequate pain treatment have resulted in increased opioid prescribing, at times by physicians who were not adequately trained in pain and risk management.
Chemotherapy-induced peripheral neuropathy (CIPN) is a significant, debilitating complication of chemotherapy administration for cancer.
Only a small percentage of chronic pain patients receiving appropriate opioid treatment will become addicted to the medications. In fact, in their patients treated with opioids, healthcare providers are much more likely to face noncompliant behavior than frank addiction.